Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma

Key facts

Sponsor

SCRI Development Innovations, LLC

Principal Investigator

John D. Hainsworth, MD

SCRI Development Innovations, LLC

Intervention

bevacizumab(drug)

Enrollment

80 enrolled

Eligibility

18 years · All sexes

Timeline

2006 – 2011

Study locations (12)

• Florida Cancer Specialists, Fort Myers, Florida, United States
• Gainsville Hematology Oncology Associates, Gainesville, Florida, United States
• Integrated Community Oncology Network, Jacksonville, Florida, United States
• Florida Hospital Cancer Institute, Orlando, Florida, United States
• Wellstar Cancer Research, Marietta, Georgia, United States
• Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States
• Baton Rouge General Medical Center, Baton Rouge, Louisiana, United States
• Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States
• Methodist Cancer Center, Omaha, Nebraska, United States
• Oncology Hematology Care, Cincinnati, Ohio, United States
• Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
• Tennessee Oncology, PLLC, Nashville, Tennessee, United States

Collaborators

Genentech, Inc. · Novartis

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Clear cell renal carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07128680
  Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
  City of Hope Medical Center
• RECRUITINGPHASE2NCT06863311
  Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
  Karie Runcie
• RECRUITINGPHASE2NCT07397611
  Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
  Dana-Farber Cancer Institute
• RECRUITINGPHASE2NCT07188896
  A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
  Brian Rini
• RECRUITINGPHASE2NCT07469683
  An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
  Yonsei University
• RECRUITINGPHASE1, PHASE2NCT07227415
  A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
  Pfizer
• RECRUITINGPHASE1, PHASE2NCT07551349
  Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
  Beijing Biotech
• RECRUITINGPHASE2NCT07223541
  Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
  University of Oklahoma

See all trials for Clear cell renal carcinoma →